# EDGAR Filing Document

**Accession Number:** 0001894562
**File Stem:** 0001628280-26-026701
**Filing Date:** 2026-4
**Character Count:** 4222
**Document Hash:** 42428603b9aa30d879686b8e438486bf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-026701.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001628280-26-026701

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prime Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001894562
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41536
- **FILM NUMBER:** 26885745

**BUSINESS ADDRESS:**
- **STREET 1:** 60 FIRST ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-465-0013

**MAIL ADDRESS:**
- **STREET 1:** 60 FIRST ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

![](a2026proxycardnotice001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 PRIME MEDICINE, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement if other than Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

------

![](a2026proxycardnotice002.jpg)

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V90550-P48669 \*Please check the meeting materials for any special requirements for meeting attendance. PRIME MEDICINE, INC. 60 FIRST STREET CAMBRIDGE, MA 02141 PRIME MEDICINE, INC. 2026 Annual Meeting Vote by June 4, 2026 11:59 PM ET You invested in PRIME MEDICINE, INC. and it's time to vote! You have the right to vote on proposals being presented at the 2026 Annual Meeting. Important Notice Regarding the Availability of Proxy Materials for the 2026 Annual Meeting of Stockholders to be Held on June 5, 2026. Vote Virtually at the Meeting\* June 5, 2026 2:00 PM ET Virtually at: www.virtualshareholdermeeting.com/PRME2026 Get informed before you vote View the Notice, Proxy Statement and 2025 Annual Report online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2026. If you would like to request a copy of the material(s) for this and/or future annual stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 (toll-free from the U.S., U.S. territories and Canada) or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

------

![](a2026proxycardnotice003.jpg)

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". Voting Items Board Recommends V90551-P48669 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming 2026 Annual Meeting. Please follow the instructions on the reverse side to vote these important matters. 1. To elect Michael Kelly and David Schenkein, M.D. as Class I Directors. For Nominees: 01) Michael Kelly 02) David Schenkein, M.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For NOTE: Such other business as may properly come before the meeting or any continuations, adjournments, and postponements thereof.

------